Overview

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy subjects. The study is approximately 12 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Glargine